Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-md8df Total loading time: 2.535 Render date: 2021-12-03T23:49:05.253Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Perampanel

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Auvin, S, Dozieres, B, Ilea, A, Delanoë, C. Use of perampanel in children and adolescents with Lennox–Gastaut syndrome. Epilepsy and Behavior 2017; 74: 5963.CrossRefGoogle ScholarPubMed
Besag, FMC, Patsalos, PN. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatric Decease and Treatment 2016; 12: 12151220.Google ScholarPubMed
Crespel, A, Gelisse, P, Tang, NPL, Genton, P. Perampanel in 12 patients with Unverricht–Lundborg disease. Epilepsia 2017; 58: 543547.CrossRefGoogle ScholarPubMed
French, JA, Krauss, GL, Biton, V, Squillacote, D, Yang, H, Laurenza, A, Kumar, D, Rogawski, MA. Adjunctive perampanel for refractory partial-onset seizures. Randomized phase III study 304. Neurology 2011; 79: 589596.CrossRefGoogle Scholar
French, JA, Krauss, GL, Wechsler, RT, Wang, XF, DiVentura, B, Brandt, C, Trinke, E, O’Brien, TJ, Laurenza, A, Patten, A, Bibbiani, F. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology 2015; 85: 950957.CrossRefGoogle ScholarPubMed
Goldsmith, D, Minassian, BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy and Behavior 2016; 62: 132135.CrossRefGoogle ScholarPubMed
Hanada, T, Hashizume, Y, Tokuhara, N, Takenaka, O, Kohmura, N, Ogasawara, A, Hatekeyama, S, Ohgoh, M, Ueno, M, Nishizawa, Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptotr antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52: 13311340.CrossRefGoogle ScholarPubMed
Heyman, E, Lahat, E, Levin, N, Epstein, O, Lazinger, M, Berkovitch, M Gandelman-Marton, R. Tolerability and efficacy of perampanel in children with refractory epilepsy. Developmental Medicine and Child Neurology 2017; 59: 441444.CrossRefGoogle ScholarPubMed
Krauss, GL, Bar, M, Biton, V, Klapper, JA, Rektor, I, Vaiciene-Magistris, N, Squillacote, D, Kumar, D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurologica Scandinavica 2012; 125: 815.CrossRefGoogle ScholarPubMed
Krauss, GL, Serratosa, JM, Villanueva, V, Endziniene, E, Hong, Z, French, J, Yang, H, Squillacote, D, Edwards, HB, Zhu, J, Laurenza, A. Randomized phase III study 306. Adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78: 14081415.CrossRefGoogle ScholarPubMed
Ledingham, DRM, Patsalos, PN. Perampanel: what is its place in the management of partial epilepsy? Neurology and Therapy 2013; 2: 1324.CrossRefGoogle Scholar
Leppik, IE, Wechsler, RT, Williams, B, Yang, H, Zhou, S, Laurenza, A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Research 2015; 110: 216220.CrossRefGoogle ScholarPubMed
Patsalos, PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 2015; 56: 1227.CrossRefGoogle ScholarPubMed
Patsalos, PN. Gougoulaki, N, Sander, JW. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex and concomitant anti-epileptic drugs. Therapeutic Drug Monitoring 2016; 38: 358364.CrossRefGoogle ScholarPubMed
Patsalos, PN, Zugman, M, Lake, C, James, A, Ratnaraj, N, Sander, JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia, 2017; 58: 12341243.CrossRefGoogle Scholar
Redecker, J, Wittstock, M, Benecke, R, Rosche, J. Efficacy of perampanel in refractory nonconvulsive stutas epilepticus and simple partial status epilepticus. Epilepsy and Behavior 2015; 45: 176179.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×